All In Biotech

Drug Trial Radar · NCT04277624

A Study to Assess Bioequivalence of Fezolinetant Formulations in Healthy Female Participants

A Phase 1 Crossover Study to Assess the Bioequivalence of Fezolinetant Following a Single Dose of Fezolinetant (Test Formulation) Compared to a Single Dose of Fezolinetant Phase 3 Formulation (Reference Formulation) in Healthy Female Subjects

Last checked: Nov 20, 2026Latest source record: Oct 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

22

Actual

Start

Feb 20, 2020

Primary completion

Feb 21, 2021

Study completion Feb 26, 2021

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Feb 20, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the bioequivalence of a single dose of fezolinetant test formulation compared to a single dose of fezolinetant reference formulation under fasting conditions. This study will also evaluate the safety and tolerability of a single dose of fezolinetant test formulation and a single dose of fezolinetant reference formulation.

Conditions

  • Healthy Volunteers

Interventions

  • fezolinetant - test formulationDrug

    Administered orally

  • fezolinetant - reference formulationDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pharmacokinetics (PK) of fezolinetant in plasma: Area under the concentration-time curve (AUC) from the time of dosing extrapolated to time infinity (AUCinf)Time frame: Up to 72 hours postdose in each study period
  2. Pharmacokinetics (PK) of fezolinetant in plasma: Area under the concentration-time curve (AUC) from the time of dosing to the last measurable concentration (AUClast)Time frame: Up to 72 hours postdose in each study period
  3. Pharmacokinetics (PK) of fezolinetant in plasma: Maximum concentration (Cmax)Time frame: Up to 72 hours postdose in each study period

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PAREXEL Early Phase Clinical Unit

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.